Aktienanalyse zu Pediatrix Medical Group Inc (MD)MDPediatrix Medical Group Inc

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. It operates in the Healthcare sector (SERVICES-HOSPITALS industry).

Pediatrix Medical Group Inc is currently trading at $26.64, which is close to the average analyst price target of $28, suggesting limited upside potential. The RSI is at 68.631, indicating it is approaching overbought territory, which could lead to a price correction. Additionally, the stock has shown a strong year-to-date change of +25.13% and a one-year change of +65.98%, but the recent downgrade from Jefferies highlights potential risks ahead, particularly with earnings growth expected to cap due to tax credit headwinds.

14 analysts cover MD: 3 rate it Buy, 10 Hold and 1 Sell. The average price target is 23.50.